Last reviewed · How we verify
Dabigatran and pitavastatin oral solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dabigatran and pitavastatin oral solution (Dabigatran and pitavastatin oral solution) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dabigatran and pitavastatin oral solution TARGET | Dabigatran and pitavastatin oral solution | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dabigatran and pitavastatin oral solution CI watch — RSS
- Dabigatran and pitavastatin oral solution CI watch — Atom
- Dabigatran and pitavastatin oral solution CI watch — JSON
- Dabigatran and pitavastatin oral solution alone — RSS
Cite this brief
Drug Landscape (2026). Dabigatran and pitavastatin oral solution — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-and-pitavastatin-oral-solution. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab